Neuberger Berman Group
EWTX icon

Neuberger Berman Group’s Edgewise Therapeutics EWTX Stock Holding History

Neuberger Berman Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.77M Buy
191,195
+22,517
+13% +$776K 0.01% 951
2026
Q1 		$5.31M Buy
168,678
+41,542
+33% +$1.2M ﹤0.01% 970
2025
Q4 		$3.15M Sell
127,136
-92,510
-42% -$1.86M ﹤0.01% 1064
2025
Q3 		$3.56M Buy
219,646
+54,111
+33% +$768K ﹤0.01% 1037
2025
Q2 		$2.17M Buy
165,535
+63,354
+62% +$914K ﹤0.01% 1148
2025
Q1 		$2.25M Buy
+102,181
New +$2.68M ﹤0.01% 1105

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group's EWTX Position: Q2 2026 in Review

Neuberger Berman Group increased its Edgewise Therapeutics (EWTX) stake by 13% in Q2 2026, buying an estimated $776K and bringing the position to 191,195 shares worth $7.77M. The position accounts for 0.01% of the portfolio, ranked #951.

Neuberger Berman Group first reported a position in EWTX in Q1 2025 and has held it in 6 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Neuberger Berman Group held 191,195 shares of Edgewise Therapeutics worth $7.77M as of Q2 2026.
  • Neuberger Berman Group bought 22,517 Edgewise Therapeutics shares in Q2 2026, an estimated $776K.
  • Edgewise Therapeutics made up 0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #951 holding.
  • Neuberger Berman Group first reported a position in Edgewise Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.